8 completed, 1 withdrawn. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Phase 2 | 4 | Completed 4 |
Follow Themis Bioscience GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract TMV-018 + 5-FC, TMV-018 + anti-PD-1, TMV-018 + 5-FC + anti-PD-1 - Gastrointestinal Cancer | Phase 1 | Withdrawn | Themis Bioscience GmbH | 2020-11-23 | 2020-11-25 | |
| Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose, Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose, One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose - COVID-19 | Phase 1 | Completed | Institut Pasteur | 90 | 2020-08-10 | 2022-02-18 |
| A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001) MV-LASV, Placebo - Lassa Virus Infection | Phase 1 | Completed | Themis Bioscience GmbH | 60 | 2019-09-26 | 2025-07-11 |
| Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001) Two MV-ZIKA-RSP vaccinations (high dose), Two MV-ZIKA-RSP vaccination (low dose), One MV-ZIKA-RSP vaccination (high dose) and one placebo - Zika Virus Infection | Phase 1 | Completed | Themis Bioscience GmbH | 48 | 2019-08-02 | 2021-12-06 |
| Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) V184, Placebo - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 41 | 2019-07-16 | 2022-09-08 |
| Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) MV-CHIK lyophilised formulation, low dose, MV-CHIK liquid frozen formulation, low dose, MV-CHIK SPS® formulation, low dose - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 60 | 2018-08-22 | 2021-10-22 |
| Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area MV-CHIK, MMR-vaccine - Chikungunya | Phase 2 | Completed | Themis Bioscience GmbH | 34 | 2017-08-09 | 2021-07-19 |
| Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001) MV-ZIKA, Placebo - Zika Virus | Phase 1 | Completed | Themis Bioscience GmbH | 48 | 2017-05-03 | 2022-08-18 |
| Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine MV-CHIK low dose, MV-CHIK high dose, Priorix® - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 263 | 2016-08-17 | 2021-10-29 |
Chikungunya Fever (4) · Zika Virus Infection (2) · COVID-19 (1) · Colorectal Neoplasms (1) · Communicable Diseases (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Lassa Fever (1) · Stomach Neoplasms (1)
Measles-Mumps-Rubella Vaccine (2) · Dosage Forms (1) · Flucytosine (1) · Organization and Administration (1) · Sodium Chloride (1)
Austria (3) · Belgium (2) · Germany (2) · Puerto Rico (2) · France (1) · United Kingdom (1)
Clemente Diaz, MD (1) · Ulrich Lauer, MD (1)
PMID 25739878, PMID 30409443, PMID 31053842, PMID 34582377, PMID 35045362, PMID 36934733
2018 (2), 2015 (1), 2016 (1), 2019 (1)